Immunovant, Inc. (IMVT) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted General and Administrative Expense | 12.4M | FY2026-Q4 |
| Adjusted Research and Development Expense | 136M | FY2026-Q4 |
| Mean Immunoglobulin G Reduction at Week 12 (Higher Dose Arm) | 74.00 percent | FY2025-Q4 |
| Mean Immunoglobulin G Reduction at Week 12 (Lower Dose Arm) | 64.00 percent | FY2025-Q4 |
Back to IMVT overview · IMVT earnings · IMVT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.